[EN] GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS<br/>[FR] COMPOSÉS GLYCOMIMÉTIQUES EN TANT QU'AGENTS ANTI-INFECTIEUX CONTRE DES LECTINES PATHOGÈNES
申请人:CENTRE NAT RECH SCIENT
公开号:WO2012076934A1
公开(公告)日:2012-06-14
The present invention relates to a calixarene-based glycosylated compound (I) having the formula : (I) wherein D is independently selected in the group comprising a –CH2 –group, an oxygen atom, a sulphur atom, a sulfinyl group or a sulfonyl group, E is independently selected in the group comprising a hydrogen, an alkyl having from 1 to 10 carbon atoms, an aryl having from 6 to 20 carbon atoms, a nitrogen dioxide group, an azide group, an amino group, a guanidinium group,a halogen atom, a –CH2 R group wherein R is a hydroxyl, a halogen, an amino group, a N(alkyl)2 group, a NH(alkyl) group, or E represents a –CO-R' wherein R' is a hydrogen atom, a hydroxyl group or an amino, B represents a A–C group wherein A is independently selected in the group comprising an oxygen atom, a sulfur atom, a NH group or a (CH2 )i group, i being an integer from 1 to 10, C is independently selected in the group comprising a hydrogen, an alkyl, an alkenyl, an alkynyl, or C is a group of formula (II). The present invention also relates to a pharmaceutical composition characterized in that it comprises the said calixarene-based glycosylated compound (I), in combination with pharmaceutically acceptable carriers or diluents. The present invention also relates to the use of the said calixarene-based glycosylated compound (I) or the said pharmaceutical composition, for the manufacture of a drug intended to prevent or treat bacterial infections from pathogens that use lectins in the first steps of infection.
本发明涉及一种基于杯芳烃的糖基化化合物(I),其化学式为:(I),其中D在以下基团中独立选择:-CH2-基团、氧原子、硫原子、亚砜基团或磺基团,E在以下基团中独立选择:氢、碳原子数为1至10的烷基、碳原子数为6至20的芳基、二氧化氮基团、叠氮基团、氨基团、胍基团、卤素原子、-CH2R基团,其中R为羟基、卤素、氨基、N(烷基)2基团、NH(烷基)基团,或E表示-CO-R',其中R'为氢原子、羟基或氨基,B表示A-C基团,其中A在以下基团中独立选择:氧原子、硫原子、NH基团或(CH2)i基团,i为1至10的整数,C在以下基团中独立选择:氢、烷基、烯基、炔基,或C为下式的基团(II)。本发明还涉及一种药物组合物,其特征在于它包括所述基于杯芳烃的糖基化化合物(I),结合具有药用接受的载体或稀释剂。本发明还涉及所述基于杯芳烃的糖基化化合物(I)或所述药物组合物的用途,用于制造预防或治疗利用凝集素在感染的最初阶段的病原体引起的细菌感染的药物。